- No posts yet.
- HIQA publishes batch of inspection reports revealing compliance gaps in older people and disability services across Ireland 7-day briefing • 2026-07-21 - 2026-07-27
- HIQA publishes 73 inspection reports on older people and disability residential centres with mixed compliance results 7-day briefing • 2026-07-20 - 2026-07-26
- HIQA publishes updated list of 38 designated disability centres across Ireland. 7-day briefing • 2026-07-13 - 2026-07-19
- HIQA annual report reveals expanded regulatory scope including private hospital inspections and home support licensing 7-day briefing • 2026-06-29 - 2026-07-05
- HIQA solidifies dual evidence-regulatory role; HSE workforce crisis fades from weekly briefings. 30-day briefing • 2026-05-24 - 2026-06-22
- HIQA publishes alcohol risk models, mental health review, and HTA protocol for severe neurological impairment 7-day briefing • 2026-06-15 - 2026-06-21
- First human trial of AI-designed universal coronavirus vaccine and promising cancer drug results lead medical advances this week 7-day briefing • 2026-05-31 - 2026-06-06
- Ireland unveils Sláintecare 2025+ roadmap and 2026 Waiting List Plan amid HSE briefing revealing systemic staffing and capacity deficits. 7-day briefing • 2026-05-24 - 2026-05-30
- Rapid Review of Rozanolixizumab (Rystiggo) for gMG Completed by NCPE ncpe.ie | 59d ago
- NCPE Rapid Review Recommends Full HTA for Zilucoplan (Zilbrysq) for Generalized Myasthenia Gravis ncpe.ie | 61d ago
- NCPE Recommends Against Reimbursement of Belzutifan (Welireg) for von Hippel-Lindau Disease in Ireland ncpe.ie | 63d ago
- Ireland's health system faces record waiting lists and low booster uptake as new plans draw criticism 7-day briefing • 2026-05-17 - 2026-05-23
- Ireland's health system under sustained pressure with record waiting lists and low vaccine uptake; no material change over the period. 30-day briefing • 2026-04-24 - 2026-05-23
- NCPE Ireland HTA for Opdualag (nivolumab+relatlimab) for advanced melanoma: status update ncpe.ie | 66d ago
- Dostarlimab (Jemperli) – NCPE Rapid Review Recommends Full HTA for Endometrial Cancer ncpe.ie | 67d ago
- NCPE Assessment: Belzutifan not cost-effective for VHL disease-associated tumours at current price ncpe.ie | 87d ago
- NCPE Recommends Belzutifan (Welireg) Not Reimbursed for VHL Disease on Cost-Effectiveness Grounds ncpe.ie | 87d ago
- National Centre for Pharmacoeconomics Publishes Budget Impact Guideline Version 1.1 ncpe.ie | 105d ago
- NCPE Publishes Updated Budget Impact Model Template v2.3 for Drug Reimbursement Submissions ncpe.ie | 105d ago
- NCPE Releases Full HTA Submission Template Version 3.1 for Pharmacoeconomic Assessments in Ireland ncpe.ie | 676d ago
Showing page 1 of 2
(28 total results)
← Prev
Next →